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Abstract
Background: Prader-Willi Syndrome (PWS) is a rare genetic, metabolic disorder affecting both males and
females equally. Along with compulsive and gluttonous eating, affected youth also suffer from varying degrees
of mental retardation and decreased sexual development. Being physically underdeveloped as compared to
their peers may make children suffering from PWS more self-conscious, and more likely to suffer from
behavior disturbances. Studies have shown some positive response to exogenous administration of human
chorionic gonadotropin (hCG) in the stimulation of sex hormones as well as development of secondary sex
characteristics. Traditional treatment with testosterone has led to increased aggression, and exacerbation of
PWS behavioral disturbances. hCG has been shown to improve virility in male patients, without the negative
behavioral effects seen in testosterone treatment. To this point, only case studies and anecdotal evidence have
been available. Could the lives of youth suffering from this disorder be improved with carefully timed
administration of hCG?
Methods: An exhaustive search of the literature was conducted using Medline/OVID, NCBI/PubMed, Web
of Science, and CINAHL using the key words: Prader-Willi Syndrome, and hCG. Relevant articles were
assessed for quality using GRADE. There are no currently registered NIH clinical trials involving the
treatment of hypogonadic peripubertal PWS patients with hCG.
Results: Two studies met inclusion criteria for this systematic review. Two clinical follow-up studies involving
6 study subjects treated with hCG injections demonstrated improved sexual maturity (as evidenced by
improved testicular volume and secondary sex characteristics) and hormonal normalization with no
significantly concerning behavioral changes.
Conclusion: hCG has been shown to improve secondary sex characteristics and hormonal levels without
negative behavioral changes in peripubertal male patients when managed by a pediatric endocrinologist. More
research is needed to determine comparisons with other existing and potential treatments, including depo-
testosterone, etc. Improved studies (including RCTs) and study designs could also further improvements in
the management of PWS-hypogonadism. Challenges include the global rarity of the disease, and finding
enough subjects to provide adequate study populations.
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ABSTRACT  
Background: Prader-Willi Syndrome (PWS) is a rare genetic, metabolic disorder affecting both 
males and females equally. Along with compulsive and gluttonous eating, affected youth also 
suffer from varying degrees of mental retardation and decreased sexual development. Being 
physically underdeveloped as compared to their peers may make children suffering from PWS 
more self-conscious, and more likely to suffer from behavior disturbances. Studies have shown 
some positive response to exogenous administration of human chorionic gonadotropin (hCG) in 
the stimulation of sex hormones as well as development of secondary sex characteristics. 
Traditional treatment with testosterone has led to increased aggression, and exacerbation of PWS 
behavioral disturbances. hCG has been shown to improve virility in male patients, without the 
negative behavioral effects seen in testosterone treatment. To this point, only case studies and 
anecdotal evidence have been available. Could the lives of youth suffering from this disorder be 
improved with carefully timed administration of hCG?  
 
Methods: An exhaustive search of the literature was conducted using Medline/OVID, 
NCBI/PubMed, Web of Science, and CINAHL using the key words: Prader-Willi Syndrome, and 
hCG. Relevant articles were assessed for quality using GRADE. There are no currently 
registered NIH clinical trials involving the treatment of hypogonadic peripubertal PWS patients 
with hCG. 
 
Results: Two studies met inclusion criteria for this systematic review. Two clinical follow-up 
studies involving 6 study subjects treated with hCG injections demonstrated improved sexual 
maturity (as evidenced by improved testicular volume and secondary sex characteristics) and 
hormonal normalization with no significantly concerning behavioral changes. 
 
Conclusion: hCG has been shown to improve secondary sex characteristics and hormonal levels 
without negative behavioral changes in peripubertal male patients when managed by a pediatric 
endocrinologist. More research is needed to determine comparisons with other existing and 
potential treatments, including depo-testosterone, etc. Improved studies (including RCTs) and 
study designs could also further improvements in the management of PWS-hypogonadism. 
Challenges include the global rarity of the disease, and finding enough subjects to provide 
adequate study populations. 
 
Key words: Prader-Willi Syndrome, hCG (human chorionic gonadotropin), hypogonadism 
 
  
 3 
Table of Contents 
 
Abstract.......................................................................................................2 
Table of Contents........................................................................................3 
List of Tables...............................................................................................4 
 GRADE tables.................................................................................4 
List of Abbreviations...................................................................................4 
Background.................................................................................................5 
Methods.......................................................................................................7 
Results.........................................................................................................7 
Discussion...................................................................................................12 
Conclusion..................................................................................................14 
References...................................................................................................16 
Tables..........................................................................................................17 
  
 4 
LIST OF TABLES 
Table 1: GRADE Quality of Assessment and Summary of Findings 
 
LIST OF ABBREVIATIONS 
  
PWS Pradder-Willi Syndrome 
hCG human chorionic gonadotropin 
BA Bone age 
CA Chronological age 
GH Growth hormone 
LH Leutinizing hormone 
FSH Follicle stimulating hormone 
WFH Weight for height 
  
 5 
Human chorionic gonadotropin (hCG) for Improved Virility without Negative Behavioral 
Changes in Hypogonadotropic Hypogonadic Adolescent Males with Prader-Willi 
Syndrome 
BACKGROUND 
 Prader-Willi Syndrome (PWS) is a rare genetic, metabolic syndrome affecting both males 
and females equally, caused by a faulty expression of the paternal PWS segment on chromosome 
15q11.2-q13.1 Diagnosis is confirmed with genetic testing generally in response to abnormal 
infantile development. Prevalence in the United States is approximately 1:15 000-25 000, with 
roughly 400 000 individuals affected worldwide.2,3 Treatment efficacy is closely related to the 
age of diagnosis, but due to the rarity of the syndrome PWS can often be missed by pediatricians 
and primary care providers.  PWS patients suffer with compulsive and gluttonous eating, varying 
degrees of mental retardation, specific physical dysmorphisms and late or decreased sexual 
development. Human growth hormone (GH) was approved by the FDA for treatment of PWS in 
2000, and has been shown to improve lean muscle mass, bone density abnormalities, and 
normalize height, but fails to correct hypogonadism and subsequent sequelae.4   
Hypogonadism can usually be attributed to various degrees of hypothalamic dysfunction. 
Much evidence points to a deficit in the hypothalamic-pituitary-gonadotropin axis in boys with 
PWS, but there are also elements of primary hypogonadism.5  Hypothalamic disorders may be 
suggested with low leutinizing hormone (LH). Primary failure involving the testes generally 
demonstrates low inhibin B and high follicle-stimulating hormone (FSH) levels, indicating a 
defect in Sertoli and/or germ cell maturation or an early germ cell loss.6  Testicular histology 
also varies significantly, with cryptorchidism being much more common in PWS males. 
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Hypogonadism found in PWS has been historically difficult to study as the endocrine 
component of the disease state is complicated, paired with the relative rarity of the disease. Most 
articles identified in the literature focus on individual case studies or small groups of patients and 
lack the depth and clinical significance of randomized control trials or other robust study 
designs. The specific components of the hypothalamic hypogonadic aspect of the disease are 
better understood now, but treatment plans are still generally determined by individual 
endocrinologists without well-defined standard guidelines.  
Testosterone undecanoate is the FDA-approved medication for use in primary 
hypogonadism, as well as hypogonadic hypogonadism in male patients. Improved virilization 
and balance of serum hormone levels are common using testosterone treatments, however 
adverse drug reactions including mood swings, agitation, irritability, and insomnia are frequently 
found.7 Increases in serum testosterone levels were inconsistent, as has been the regulation and 
normalization of FSH and LH.  
Another hormone to consider in treating hypogonadism is hCG, however, previous 
studies have noted varied response to therapy with hCG in hypogonadic patients without PWS.8 
Furthermore, there has been hesitation to treat PWS patients with exogenous sex hormones, like 
testosterone and hCG, over concerns that therapy frequently exacerbates pre-existing problems 
found in PWS patients. hCG treatment in PWS patients allows for improved control and 
adjustment of dosing preventing major fluctuations of testosterone, as hCG stimulates testicular 
development and subsequent release of endogenous testosterone and other sex hormones as well 
as development of secondary sex characteristics. 9  To this point, only case studies and anecdotal 
evidence have been available.  
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Exogenous administration of hCG has potential to improve the symptoms of PWS, 
without the high adverse drug reaction profile commonly found in treatment with exogenous sex 
hormones. Medication can be carefully titrated to avoid adverse effects, and have more regulated 
therapeutic response. Studies involving treatment with hCG are limited, but show promise. More 
studies involving larger populations of subjects are vital to improving the lives of these patients. 
Could the administration of exogenous hCG in the treatment of Prader-Willi Syndrome-
associated hypogonadism improve virility, behavior, and secondary sex characteristic 
presentation in peripubertal male patients? 
METHODS 
 An exhaustive search of the available literature was conducted using Medline/OVID, 
NCBI/PubMed, Web of Science, CINAHL and the key words: Prader-Willi Syndrome, and hCG 
(human chorionic gonadotropin). The search was narrowed by including English language 
articles involving adolescent male subjects. Abstracts were reviewed, with relevant articles being 
reviewed in their entirety. Bibliographies of pertinent articles were reviewed. Relevant articles 
were assessed for quality using the GRADE criteria (Grading of Recommendations, Assessment, 
Development, and Education).10 There are currently no registered NIH clinical trials involving 
the treatment of hypogonadic peripubertal PWS patients with hCG. 
RESULTS 
 The initial result of the search including "Prader-Willi Syndrome" with "Chorionic 
Gonadotropin/hcg” yielded 191 articles for review in the English language. After careful review 
of these articles, 16 met the inclusion criteria for primary data involving human subjects. As 
PWS-related hypothalamic hypogonadism is such a unique disorder among other metabolic 
genetic diseases, articles included were limited to those dealing with PWS-specific 
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hypogonadism being treated with hCG, excluding other forms of hypogonadism.  These articles 
were narrowed down to two "clinical follow-up" studies.9,11 See Table I. 
EIHOLZER et al (2006) 
 This study is described as a “clinical follow-up” study with the intent to investigate the 
cause of PWS hypogonadism as well as determine whether the exogenous administration of hCG 
at pubertal failure can restore development and Leydig cell function. Patients were divided into 
two samples; 8 infants and 6 peripubertal boys. The study was conducted over 1.5 years and 4.5 
years (respectively) at the Institute Growth Puberty Adolescence, a pediatric endocrine specialty 
center in Zurich, Switzerland. All study subjects had genetically confirmed PWS at the time of 
enrollment in the study. Considering ethical limitations, the study was observation only, with no 
specific age-matched control group.11 
 The infants initially had normal values for serum testosterone, LH, and inhibin B, but 
increased FSH as compared to age-appropriate reference range. However, testosterone, LH, 
inhibin B, and FSH all began to gradually decline between the ages of 5 and 18 months. Values 
were analyzed for differences between boys with normally descended testicles as compared to 
those with either unilateral or bilateral cryptorchidism. No differences in hormonal values were 
noted in those children with normally descended testes as compared to those with maldescent. 
Infants were given daily injections of recombinant human GH (Genotropin); 6 mg/m2 weekly, 
beginning therapy at 6 months (n=2), 12 months (n=3), and 18 months (n=3).11 
 The primary outcome studied in the adolescent participants (n=6) was gonadal function 
prior to and during puberty. Subjects were retrospectively analyzed every 6 months from 10-17 
years of age. At each visit patients were measured for height and weight, Tanner pubertal 
staging, and testicular volume. The boys were X-rayed to determine bone age every 12 months, 
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whereas pubertal boys were scanned every 6-9 months. Serum FSH, LH, inhibin B, and 
testosterone levels were drawn and compared to age-dependent values of comparable reference 
ranges. Serum IGF-I levels and height had previously been normalized using standard human 
growth hormone therapy. Twice weekly intramuscular (IM) hCG injections were initiated for 
bone ages 13-16 years at evidence of pubertal arrest, mean age 13.9 years. Pubertal arrest was 
determined by stabilization of testicular volume around 4.0 ml, additional lack of testosterone 
increase, and bone maturation. Most had full pubic hair development (Tanner Stage 5) at 
pubertal arrest. Inhibin B levels were below normal, LH and testosterone levels were in the lower 
normal range until age 13 years. There was 500 U of hCG administered to boys with bone age 
13-13.5 years, 1000 U hCG administered to 13.6-14.5 years, and 1500 U for boys older than 14.5 
years.11 
 Treatment with hCG improved Leydig cell response; increasing serum testosterone 2.8 
fold to low-normal levels, reducing FSH levels 3 fold, and maintaining LH levels. However, 
even with an increase in testosterone level, there failed to be an increased secretion of inhibin B. 
The authors concluded that this most likely indicates a Sertoli cell dysfunction of tubular origin, 
which could not clearly be explained by the cryptorchidism commonly found in most male PWS 
patients. Testicular biopsies of descended testes demonstrated absent germ cells, indicating a 
probable primary gonadal defect, combined with a hypothalamic deficit causing the peripubertal 
failure of LH increase in patients with PWS.11 
 Physical characteristics improved significantly with genitals increasing to low adult size, 
and the deepening of the voice. Most importantly; treatment with hCG led to an increase in 
testosterone and secondary sex characteristics without significant negative behavioral response. 
No increase in social or behavioral problems was noted during hCG treatment. The authors 
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suggest substitution with sex hormones at puberty for the normalization of pubertal development. 
No advances were made towards the restoration of spermatogenesis.11  
EIHOLZER et al (2007) 
 This study9 aimed to demonstrate the utility of sex hormone replacement therapy on male 
adolescent patients with PWS, in addition to GH therapy. Primary goals of the study were to 
"complete male pubertal development in a physiological, well-balanced and cautious way.”  The 
study is described as a clinical follow-up study with the intent to evaluate the effects of 
exogenous hCG on pubertal boys with PWS-associated hypogonadism. Six hypogonadic 
peripubertal boys with genetically confirmed PWS were followed for a minimum of two years, 
prior to and following pubertal arrest. All boys were already undergoing long-term treatment 
with human growth hormone (GH). Patients were treated with hCG 500-1500 IU IM twice 
weekly and evaluated every six months from age 7 to 17 years. Examinations evaluated height, 
weight, growth velocity per year, Tanner Stage of pubertal development, testicular volume, 
chronological and bone age, body composition, testosterone levels, and behavior. Questionnaires 
were administered to the parents, considering their perceived changes in the patient in question, 
and when possible, compared to siblings with normal onset puberty. The questionnaire addressed 
(1) relations to peers; (2) sexuality; (3) aggressiveness; (4) preoccupation with one's own 
appearance; (5) risky behavior; (6) retraction from social interaction; (7) mood, and (8) school 
performance, subdivided into a total of 19 items. Considering ethical limitations, the study was 
observation only, with no specific age-matched control group.9 
 Prior to treatment with hCG, bone age and pubic hair development was slightly 
accelerated. Puberty started at a mean age of 11.2, with arrest occurring at 13.5 years as 
determined by bone maturation, cessation of voice deepening and testicular growth, and 
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stabilization of serum testosterone levels. Administration of exogenous hCG led to increased and 
sustained rises in testosterone to low-normal levels, development of Tanner stage 5 pubic hair 
pattern, linear growth velocity increases, as well as deepening of the voice. Testicular volume 
increased mildly, but remained in the small to small-normal range. Lean mass and testosterone 
levels both increased in boys treated with hCG, and became either normal or low normal in 4 out 
of 5 boys. Fat mass and BMI remained elevated, but stabilized at 38%, considerably lower than 
other PWS adolescent boys without treatment.9 
 Behavioral and mood disturbances common in adolescents with PWS were divided into 
three main categories; (1) difficulties in or lack of social interaction; (2) aggressiveness or 
interpersonal conflicts; and (3) irritability or rapid mood changes. Of these three categories, 
patients being treated with hCG identified with problems with social interactions were found to 
not worsen in 3/6 patients, and improved in 2. Aggression worsened in 3/6 patients, but was 
similar to increases in aggression of 3 of 5 pubertal brothers unaffected with PWS. In this same 
category, aggressive behavior outside of the family unit decreased in 4/6. Three of six patients 
had PWS-related irritability that was considered greater than siblings without PWS, but was not 
considered altered during therapy. Sexuality and sexual arousal was less of a problem in patients 
with PWS, and were less difficult in patients when treated with hCG.9 
 The authors concluded that exogenous hCG improves pubertal development and muscle 
mass, without the negative behavioral components found in patients treated with exogenous 
testosterone and other sex hormones. Treatment with hCG did not appear to increase problematic 
behaviors, including relations with peers, sexuality, aggressiveness, participation in risky 
behaviors, social retractions, or irritability. However, knowledge that their children were being 
treated with hCG may have introduced bias, potentially affecting the way in which parents 
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answered the behavioral questionnaire. Treatment with hCG did appear to improve growth 
velocity in boys without spontaneous growth spurts, however, patients were not able to generate 
viable sperm, and testicles did not achieve a volume greater than 6 ml. Researchers suggest 
initiation of sex hormone in PWS with hypogonadism at pubertal failure, or 13-14 years of age. 
 Future research regarding increased adolescent psychotic episodes in PWS patients being 
treated with sex hormones is recommended by the authors of this study. It is unclear if hCG 
treatment leads to similar increases in psychotic deterioration as found with testosterone 
treatment. Comparisons between therapy with hCG and testosterone are also recommended, 
especially including larger study and control groups. 
DISCUSSION 
 Hypogonadism in boys with PWS stems from poorly understood hypothalamic and 
gonadal failure. Infants identified with severe hypotonia and poor feeding can be confirmed to 
have PWS via genetic testing. Treatment for PWS generally begins in infancy with regular 
administration of GH to normalize body mass and skeletal growth. PWS patients have a form of 
hypogonadism that is specific to this syndrome, and is unique compared to other hypothalamic 
hypogonadic disorders. Infants generally present with normal serum levels of LH and 
testosterone, but gradually declining inhibin B levels and rising FSH, fail to complete adult 
sexual development. Administration of sex hormones including testosterone has been shown to 
improve sexual development and maturity, but often have undesired behavioral effects. As 
demonstrated by these two studies,11,9 hCG is an alternative therapy that may combine the 
desired therapeutic benefits of androgens, without the adverse drug reactions. hCG has been used 
successfully in treating patients with other forms of hypogonadism including hypopituitarism 
and hypogonadotropic hypogonadism and holds potential in treating patients with PWS. 
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When combined with traditional GH therapy, hCG improves virilization, hormone profiles and 
has less negative behavioral effects than treatment with testosterone. While there have been 
promising case studies, and small group clinical observation studies, results are generally not 
complete enough or lack evidence to include in approved treatment regimens. Further research 
into better understanding the origins of the endocrine dysfunction and specific treatments for 
PWS are important, however unlikely due to the rarity of the syndrome, and the lack of rigorous 
clinical studies. 
 Research in this field is limited. Studies have been completed regarding various 
hypothalamic, hypogonadotropic, and hypogonadic disorders, but the actual etiology of PWS is 
poorly understood. Both studies9,11 involved a very small group of adolescent boys with PWS. 
Eiholzer et al (2006)11 and Eiholzer et al (2007)9 both indicated that the use of hCG can be as 
effective as testosterone undecanoate when used in the treatment of hypogonadism of PWS boys, 
however, both studies demonstrate significant limitations. Both were described as “clinical 
follow-up” studies, clearly lacking blinding and randomization. While treatment effect may be 
measured, without comparable control values, it is difficult to confidently determine the success 
of therapy. It was also noted that questionnaire answers might have been influenced by parents’ 
knowledge that their child was being treated with a medication hoped to reduce negative 
behaviors. See Table I. 
 The treatment of PWS patients is complex, and frequently beyond the realm of the typical 
primary care provider. Patients are best managed in a team approach utilizing primary care, 
pediatric endocrinologists, behavioral and mental health specialists, dieticians and social 
workers. The role of the family provider should be one of support and management of the whole 
patient. Decisions to start a patient on hormone therapy should be a conversation between the 
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provider and the patient’s parents at diagnosis of PWS, as well as arrival at puberty. Benefits and 
potential risks of therapy should be clearly and carefully enumerated. Initiation of therapy should 
involve an endocrinologist, preferably with experience treating children with PWS or other 
hypogonadic disorders. Treatment with hCG should be included in the conversation, frankly 
discussing known advantages and disadvantages. 
 At this time, treatment of PWS hypogonadism with hCG can be considered, but it is too 
soon to recommend it over other existing treatments. More research is needed in this area to 
better understand the effect of therapy, as well as the advantages over other existing medical 
treatments. hCG may be more appropriately reserved for patients who have intolerable adverse 
reactions to other medications. There exists little in the literature focusing on the specific PWS 
picture, and treatments appropriate for this form of hypogonadism. While more research would 
undoubtedly lead to better management, the low prevalence makes PWS a low-priority and 
difficult task in the research world. Ideally, future research would involve improved study 
designs involving larger populations, blinding and randomization, as well as comparisons 
between existing treatments, hCG, and control groups. 
CONCLUSION  
 Treatment of hypogonadic PWS boys with hCG has been shown to improve the 
symptoms associated with a poorly functioning pituitary-hypothalamic axis. Growth hormone 
improves lean muscle mass as well as linear growth and bone development, however, treatment 
with testosterone and other sex hormones has been indicated to complete pubertal development. 
Androgens have been implicated in development and exacerbation of behavioral problems. 
While hCG treatment appears to have a similar effect on improvement of pubertal development 
and secondary sexual characteristics as testosterone, it appears to lack the negative behavioral 
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profile found with patients treated with testosterone. This data is limited by the lack of good 
study designs and subject populations. Existing research is lacking in clinical strength, owing to 
it’s mostly observational and anecdotal nature. More is needed to better understand the causes of 
PWS hypogonadism, and to direct further research and treatments. Determining the efficacy of 
hCG as compared to testosterone, and to include it in standard PWS endocrine therapy in 
adolescent boys may still be forthcoming. Randomized controlled studies involving larger 
populations are crucial for evaluation.  There is ample opportunity for research into this rare 
disease, and strong clinical evidence can only further illuminate the benefits of treatment with 
hCG. 
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TABLE I. Characteristics of included studies, GRADE evidence profile: hCG for 
hypothalamic hypogonadic adolescent boys with Prader-Willi Syndrome 
Quality Assessment 
 
 
Downgrade Criteria 
Quality 
Design Limitations Indirectness Imprecision Inconsistency Publication bias likely 
EIHOLZER et al (2006)11 
 
Observational Very Seriousa
 
Not Serious Seriousb
 
Not Serious No bias likely Very Low 
EIHOLZER et al (2007)9 
 
Observational Followup Very Seriousa
 
Not Serious Seriousb
 
Not Serious No bias likely Very Low 
Abbreviations: GRADE: Grading of Recommendations, Assessments, Development and Evaluation. 
a. Both studies focused on the same experimental group of 6 peripubertal boys, no control group was specifically identified and both studies lack a control group 
b. Both studies have a very small, identical n of 6 
 
 
 
 
 
